@article{4f4a7648a1954774a284d28119a08076,
title = "Cancer Stemness Meets Immunity: From Mechanism to Therapy",
abstract = "Cancer stem cells (CSCs) are self-renewing cells that facilitate tumor initiation, promote metastasis, and enhance cancer therapy resistance. Transcriptomic analyses across many cancer types have revealed a prominent association between stemness and immune signatures, potentially implying a biological interaction between such hallmark features of cancer. Emerging experimental evidence has substantiated the influence of CSCs on immune cells, including tumor-associated macrophages, myeloid-derived suppressor cells, and T cells, in the tumor microenvironment and, reciprocally, the importance of such immune cells in sustaining CSC stemness and its survival niche. This review covers the cellular and molecular mechanisms underlying the symbiotic interactions between CSCs and immune cells and how such heterotypic signaling maintains a tumor-promoting ecosystem and informs therapeutic strategies intercepting this co-dependency.",
keywords = "T cells, cancer stem cell, immunity, immunotherapy, myeloid-derived suppressor cells, stemness, symbiotic interaction, tumor-associated macrophages",
author = "Peiwen Chen and Hsu, {Wen Hao} and Jincheng Han and Yan Xia and DePinho, {Ronald A.}",
note = "Funding Information: We thank Drs. Denise Spring, Raghu Kalluri, Linghua Wang, Shabnam Shalapour, Jian Hu, Kyle LaBella, and Deepavali Chakravarti, as well as Scientific Publications, Research Medical Library (Donald R. Norwood), and Creative Communications (David M. Aten) for their help and advice. This work was supported in part by NIH R00 CA240896 (to P.C.), NIH P50CA221747 (to P.C.), the Cancer Research Institute Irvington Postdoctoral Fellowship (to P.C.), the Harter Prize (to P.C.), the Caroline Ross Endowed Fellowship (to P.C.), The Harold C. and Mary L. Daily Endowment Fellowship (to P.C.), the Burkhart III Distinguished University Chair in Cancer Research Endowment (to R.A.D.), NIH P01 CA117969 (to R.A.D.), NIH R01 CA225955 (to R.A.D.), and NIH R01 CA231360 (to R.A.D.). P.C. and R.A.D. designed and outlined the review. P.C. prepared the figures. P.C. W.-H.H. and J.H. prepared the initial manuscript. All authors contributed to revising and writing the final version. R.A.D. is a co-founder, advisor, and director of Tvardi Therapeutics focused on the development of STAT3 inhibitors. R.A.D. is also co-founder and advisor of Asylia Therapeutics, Nirogy Therapeutics, and Stellanova Therapeutics. The other authors declare no competing interests. Funding Information: We thank Drs. Denise Spring, Raghu Kalluri, Linghua Wang, Shabnam Shalapour, Jian Hu, Kyle LaBella, and Deepavali Chakravarti, as well as Scientific Publications, Research Medical Library (Donald R. Norwood), and Creative Communications (David M. Aten) for their help and advice. This work was supported in part by NIH R00 CA240896 (to P.C.), NIH P50CA221747 (to P.C.), the Cancer Research Institute Irvington Postdoctoral Fellowship (to P.C.), the Harter Prize (to P.C.), the Caroline Ross Endowed Fellowship (to P.C.), The Harold C. and Mary L. Daily Endowment Fellowship (to P.C.), the Burkhart III Distinguished University Chair in Cancer Research Endowment (to R.A.D.), NIH P01 CA117969 (to R.A.D.), NIH R01 CA225955 (to R.A.D.), and NIH R01 CA231360 (to R.A.D.). Publisher Copyright: {\textcopyright} 2020 The Author(s)",
year = "2021",
month = jan,
day = "5",
doi = "10.1016/j.celrep.2020.108597",
language = "English (US)",
volume = "34",
journal = "Cell reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "1",
}
